Boom Supersonic Achieves Near Supersonic Speed in Latest Test Flight

US
Published:

Boom Supersonic, an aerospace company focused on commercial air travel, announced that its XB-1 prototype aircraft reached an impressive transonic speed of Mach 0.95 during its recent Test Flight 11 on January 10, 2025. The flight was conducted over the Mojave Desert in California and lasted 44 minutes, peaking at an altitude of 29,481 feet.

Founded in 2014, Boom aims to revolutionize air travel by enabling flights at speeds of Mach 1.7, significantly cutting travel times for popular routes, such as New York to London, which could take approximately three hours. The company is working to develop technology that addresses previous challenges faced by the Concorde, including operational costs and noise pollution.

The XB-1, while smaller than Boom's intended commercial aircraft, Overture, serves as a testbed for their advanced aerodynamics and propulsion technologies. Chief Test Pilot Tristan Brandenburg guided the latest flight, which aimed to evaluate the aircraft's ability to handle dynamic pressures close to those expected during supersonic travel.

Looking ahead, Boom confirmed plans for the XB-1 to break the sound barrier in early 2025. The aircraft completed 11 test flights, with the data from the latest flight now under review to determine if further transonic testing is needed before the milestone supersonic flight.

Boom Supersonic is propelling forward in the race to revive supersonic commercial travel, hoping to offer a service that balances speed with economic feasibility.

Weekly Newsletter

News summary by melangenews

Loading...

More from United States

Tragic Collision of Passenger Plane and Military Helicopter in Washington Claims 67 Lives

A catastrophic midair collision between a passenger plane and a military helicopter in Washington D.C. on Wednesday resulted in the deaths of all 67 individuals on board. The incident involved American Airlines flight 5342, which was a Bombardier CRJ-700 carrying 60 passengers and four crew members, and a military Sikorsky H-60 Black Hawk helicopter occupied by three service members. The collision occurred over the Potomac River at approximately 8:48 PM local time while the plane was making its final approach to Ronald Reagan Airport. Eyewitness reports indicated that the helicopter veered dangerously close to the aircraft before the impact, causing both to explode in midair. Emergency teams recovered 28 bodies from the plane and one from the helicopter, confirming that no survivors emerged from the wreckage. American Airlines expressed its condolences and stated that it is cooperating with investigation efforts, while President Donald Trump commented on the tragedy, stating it "seemed avoidable" given the clear weather conditions and routine approach procedure. A joint investigation by civil and military authorities is underway to determine the accident's cause.
US

FDA Approves Revolutionary Bioengineered Blood Vessel for Trauma Treatments

The U.S. Food and Drug Administration (FDA) has approved a groundbreaking bioengineered blood vessel aimed at addressing the needs of trauma patients. Developed by North Carolina-based Humacyte, this vessel is designed to integrate with a patient’s body over time, providing a solution for individuals who have suffered severe injuries that impede blood circulation, particularly in cases of amputation. According to founder and CEO Laura Niklason, traditional treatments using veins are often inadequate, especially when patients cannot provide usable options from their own bodies. The FDA approval follows extensive testing involving 51 civilian and 16 military patients, revealing that nearly 92% of the engineered vessels remained functional after 30 days, compared to 79% for synthetic alternatives. Additionally, the infection rate for the bioengineered vessels was under 1%, significantly lower than the over 8% rate associated with synthetic grafts, as published in the journal JAMA Surgery. While the approved application is limited to trauma cases, Humacyte is exploring additional uses for its technology, including potential applications in kidney dialysis and peripheral artery disease.
US

Trump Plans to Detain 30,000 Migrants at Guantanamo Bay

Former President Donald Trump has outlined a controversial plan to detain up to 30,000 migrants at the Guantanamo Bay detention facility if he is re-elected in 2024. According to a statement released by Trump's campaign, this measure aims to address illegal immigration and bolster national security. This proposal comes amidst intensifying discussions on immigration policies in the United States, reflecting Trump's previously embraced hardline stance during his presidency. Trump's administration was marked by strict immigration measures, including family separations and the construction of barriers along the U.S.-Mexico border. Critics of the plan have raised concerns about humanitarian implications and the legality of detaining a large number of migrants indefinitely. Legal experts argue that such actions could face significant pushback in courts. The proposal reflects a broader trend among certain political leaders advocating for stringent immigration control as a response to increasing cross-border migration. As the 2024 presidential election approaches, Trump's immigration policy is expected to be a focal point of debate among candidates.
US